A new recommendation from a US science panel advises that people aged 50 and older should receive the pneumococcal vaccine to protect against potentially harmful bacteria that can lead to pneumonia and other serious illnesses. The panel’s proposal suggests lowering the minimum recommended age for older adults to receive the vaccine from 65, where it currently stands. This recommendation came as the committee voted 14-1 in favour of the change during a meeting held in Atlanta.
If accepted by the Centers for Disease Control and Prevention (CDC), this updated guidance is set to have a significant impact on healthcare practices. The CDC typically follows through with committee recommendations, a move that is widely acknowledged and supported by healthcare professionals, leading to health insurers covering the costs for these recommended vaccinations.
Pneumococcal vaccinations are considered to be among the most complex recommendations issued by the government. Currently, the CDC recommends these shots for children under 5 and adults over 65 who have not been previously vaccinated against pneumococcal disease. Additionally, individuals at higher risk of contracting the disease, such as those with diabetes, chronic liver conditions, or weakened immune systems, are also encouraged to receive the vaccine.
Pneumococcal disease is caused by over 100 known types of pneumococci bacteria, which can result in severe infections affecting various parts of the body, including the lungs. In the US, there are approximately 30,000 reported cases of invasive pneumococcal disease annually, encompassing conditions like blood infections, brain and spinal inflammation, and other related illnesses, with about 30% of cases occurring in individuals aged 50 to 64.
Since the licensing of the first pneumococcal vaccine in the US in 1977, pharmaceutical companies have developed newer versions targeting multiple types in a single shot. Presently, four vaccines are in use, with the latest addition being Merck’s Capvaxive, approved by the FDA this year. This vaccine provides protection against 21 types, including eight not covered by other pneumococcal vaccines.
Looking ahead, potential concerns include the need for a booster shot in approximately 15 years and the development of new vaccines that could lead to further updates in recommendations. Dr. Jamie Loehr, chair of the committee’s pneumococcal working group, highlighted the long-standing complexity of pneumococcal vaccination guidance, emphasising the importance of minimising frequent changes in recommendations.
In summary, the recent recommendation to lower the age for pneumococcal vaccination among older adults could have a substantial impact on public health efforts in preventing pneumococcal disease and related complications. Adequate awareness and implementation of these guidelines are crucial in safeguarding the health and well-being of individuals, especially within vulnerable age groups.